144 326

Cited 4 times in

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이혜원-
dc.contributor.author전미영-
dc.contributor.author한광협-
dc.date.accessioned2019-12-18T00:48:24Z-
dc.date.available2019-12-18T00:48:24Z-
dc.date.issued2019-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173225-
dc.description.abstractBACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. METHODS: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. RESULTS: Of the total study population, 146 (43.7%) patients had HS (CAP > 238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA<12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P=0.022). CONCLUSION: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleInfluence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorDavid Sooik Kim-
dc.contributor.googleauthorMi Young Jeon-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.3350/cmh.2018.0054-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA02226-
dc.contributor.localIdA03318-
dc.contributor.localIdA03318-
dc.contributor.localIdA05405-
dc.contributor.localIdA05405-
dc.contributor.localIdA04268-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid30419649-
dc.subject.keywordAntiviral agent-
dc.subject.keywordFatty liver-
dc.subject.keywordHepatitis B, Chronic-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor전미영-
dc.contributor.affiliatedAuthor전미영-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume25-
dc.citation.number3-
dc.citation.startPage283-
dc.citation.endPage293-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.25(3) : 283-293, 2019-
dc.identifier.rimsid63781-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.